Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Net Income (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Net Income for 4 consecutive years, with -$25.3 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 61.5% to -$25.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$111.3 million through Dec 2025, up 45.63% year-over-year, with the annual reading at -$111.3 million for FY2025, 16.58% down from the prior year.
  • Net Income for Q4 2025 was -$25.3 million at Day One Biopharmaceuticals, down from -$19.7 million in the prior quarter.
  • The five-year high for Net Income was $35.8 million in Q3 2024, with the low at -$112.4 million in Q2 2024.
  • Average Net Income over 4 years is -$40.4 million, with a median of -$38.9 million recorded in 2022.
  • The sharpest move saw Net Income surged 177.66% in 2024, then plummeted 154.94% in 2025.
  • Over 4 years, Net Income stood at -$40.1 million in 2022, then crashed by 35.95% to -$54.5 million in 2023, then dropped by 20.53% to -$65.7 million in 2024, then skyrocketed by 61.5% to -$25.3 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at -$25.3 million, -$19.7 million, and -$30.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.